Search

Your search keyword '"Jacoby, Simone"' showing total 11 results
Start Over Author "Jacoby, Simone"
11 results on '"Jacoby, Simone"'

1. SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa

Author

Papot, Emmanuelle, Tovar-Sanchez, Tamara, Woods, Joana, Thaurignac, Guillaume, Eriobu, Nnakelu, Borok, Margaret, Kaplan, Richard, Avihingsanon, Anchalee, Azwa, Iskandar, Grinsztejng, Beatriz, Kumarasamy, Nagalingeswaran, Sokhela, Simiso, Mpoudi-Etame, Mireille, Arriaga, Maria, Jacoby, Simone, Matthews, Gail V., Losso, Marcelo H., Khoo, Saye, Calmy, Alexandra, Kouanfack, Charles, Ayouba, Ahidjo, Petoumenos, Kathy, Venter, W.D.Francois, Delaporte, Eric, and Polizzotto, Mark N.

Published
2024
Full Text
View/download PDF

2. SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa

Author

Papot, Emmanuelle, Tovar-Sanchez, Tamara, Woods, Joana, Thaurignac, Guillaume, Eriobu, Nnakelu, Borok, Margaret, Kaplan, Richard, Avihingsanon, Anchalee, Azwa, Iskandar, Grinsztejng, Beatriz, Kumarasamy, Nagalingeswaran, Sokhela, Simiso, Mpoudi-Etame, Mireille, Arriaga, Maria, Jacoby, Simone, Matthews, Gail V., Losso, Marcelo H., Khoo, Saye, Calmy, Alexandra, Kouanfack, Charles, Ayouba, Ahidjo, Petoumenos, Kathy, Venter, W.D. Francois, Delaporte, Eric, and Polizzotto, Mark N.

Published
2025
Full Text
View/download PDF

3. Adaption of an ongoing clinical trial to quickly respond to gaps in changing international recommendations: the experience of D 2 EFT

Author

Papot, Emmanuelle, primary, Jacoby, Simone, additional, Arlinda, Dona, additional, Avihingsanon, Anchalee, additional, Azwa, Iskandar, additional, Borok, Margaret, additional, Brown, Dannae, additional, Cissé, Mohamed, additional, Dao, Sounkalo, additional, Eriobu, Nnakelu, additional, Kaplan, Richard, additional, Karyana, Muhammad, additional, Kumarasamy, Nagalingeswaran, additional, Lee, Johnnie, additional, Losso, Marcelo H., additional, Matthews, Gail V., additional, Perelis, Leonardo, additional, Perez-Casas, Carmen, additional, Ruxrungtham, Kiat, additional, Watkins, Melynda, additional, Lane, H. Clifford, additional, Kelleher, Anthony, additional, Law, Matthew, additional, and Polizzotto, Mark N., additional

Published
2022
Full Text
View/download PDF

4. Adaption of an ongoing clinical trial to quickly respond to gaps in changing international recommendations: the experience of D2EFT

Author

Papot, Emmanuelle ; https://orcid.org/0000-0003-2782-0263, Jacoby, Simone ; https://orcid.org/0000-0001-6391-9717, Arlinda, Dona, Avihingsanon, Anchalee, Azwa, Iskandar, Borok, Margaret, Brown, Dannae, Cisse, Mohamed, Dao, Sounkalo, Eriobu, Nnakelu, Kaplan, Richard, Karyana, Muhammad, Kumarasamy, Nagalingeswaran, Losso, Marcelo H, Matthews, Gail V ; https://orcid.org/0000-0002-1048-6396, Perelis, Leonardo, Perez-Casas, Carmen, Ruxrungtham,, Kiat, Watkins, Melynda, Lane, H Clifford, Kelleher, Anthony ; https://orcid.org/0000-0002-0009-3337, Law, Matthew ; https://orcid.org/0000-0002-3540-8837, Polizzotto, Mark, Papot, Emmanuelle ; https://orcid.org/0000-0003-2782-0263, Jacoby, Simone ; https://orcid.org/0000-0001-6391-9717, Arlinda, Dona, Avihingsanon, Anchalee, Azwa, Iskandar, Borok, Margaret, Brown, Dannae, Cisse, Mohamed, Dao, Sounkalo, Eriobu, Nnakelu, Kaplan, Richard, Karyana, Muhammad, Kumarasamy, Nagalingeswaran, Losso, Marcelo H, Matthews, Gail V ; https://orcid.org/0000-0002-1048-6396, Perelis, Leonardo, Perez-Casas, Carmen, Ruxrungtham,, Kiat, Watkins, Melynda, Lane, H Clifford, Kelleher, Anthony ; https://orcid.org/0000-0002-0009-3337, Law, Matthew ; https://orcid.org/0000-0002-3540-8837, and Polizzotto, Mark

Abstract

A rapidly changing landscape of antiretrovirals and their procurement at scale has permitted the evaluation of new optimised second-line antiretroviral therapy (ART) in low- and middle-income countries. D2EFT is an open-label randomised controlled non-inferiority phase IIIB/IV trial in people living with HIV-1 (PWH) whose first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART is failing. At inception, it compared a standard of care of boosted darunavir with two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) to the novel NRTI-sparing regimen of boosted darunavir with dolutegravir. Implemented in 2017, participating sites were across Africa, Asia and Latin America. Around the time of implementation, the World Health Organization updated its treatment guidelines and recommended scaling up tenofovir disoproxil fumarate-lamivudine-dolutegravir (TLD). This situation pushed D2EFT investigators to consider the impact of the roll-out of TLD on the D2EFT research question. The protocol team agreed it was important to study TLD in second-line when an NNRTI regimen was failing, and focused on options to expedite the work by studying the question within the existing trial and network. All key issues (statistical, programmatic and financial) were reviewed to assess the benefits and risks of adding a third arm to the ongoing study, as opposed to developing a new randomised clinical trial with the same control arm and within the same network. The development of a new trial was deemed to be longer than adding a third arm, and to create a challenging situation with two competing clinical trials at the same sites which would slow down recruitment and impair both trials. On the other hand, adding a third arm would be demanding in terms of operationalisation, increased sample size and statistical biases to control. The optimal strategy was deemed to be the addition of a third arm, arriving retrospectively at a simplified multi-arm multi-stage clinical trial

Published
2022

5. Adaption of an ongoing clinical trial to quickly respond to gaps in changing international recommendations: the experience of D2EFT.

Author

Papot, Emmanuelle, Jacoby, Simone, Arlinda, Dona, Avihingsanon, Anchalee, Azwa, Iskandar, Borok, Margaret, Brown, Dannae, Cissé, Mohamed, Dao, Sounkalo, Eriobu, Nnakelu, Kaplan, Richard, Karyana, Muhammad, Kumarasamy, Nagalingeswaran, Lee, Johnnie, Losso, Marcelo H., Matthews, Gail V., Perelis, Leonardo, Perez-Casas, Carmen, Ruxrungtham, Kiat, and Watkins, Melynda

Subjects
RITONAVIR, NON-nucleoside reverse transcriptase inhibitors, REVERSE transcriptase inhibitors, CLINICAL trials, EXPERIMENTAL design, STATISTICAL bias
Abstract

A rapidly changing landscape of antiretrovirals and their procurement at scale has permitted the evaluation of new optimised second-line antiretroviral therapy (ART) in low- and middle-income countries. D2EFT is an open-label randomised controlled non-inferiority phase IIIB/IV trial in people living with HIV-1 (PWH) whose first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART is failing. At inception, it compared a standard of care of boosted darunavir with two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) to the novel NRTI-sparing regimen of boosted darunavir with dolutegravir. Implemented in 2017, participating sites were across Africa, Asia and Latin America. Around the time of implementation, the World Health Organization updated its treatment guidelines and recommended scaling up tenofovir disoproxil fumarate-lamivudine-dolutegravir (TLD). This situation pushed D2EFT investigators to consider the impact of the roll-out of TLD on the D2EFT research question. The protocol team agreed it was important to study TLD in second-line when an NNRTI regimen was failing, and focused on options to expedite the work by studying the question within the existing trial and network. All key issues (statistical, programmatic and financial) were reviewed to assess the benefits and risks of adding a third arm to the ongoing study, as opposed to developing a new randomised clinical trial with the same control arm and within the same network. The development of a new trial was deemed to be longer than adding a third arm, and to create a challenging situation with two competing clinical trials at the same sites which would slow down recruitment and impair both trials. On the other hand, adding a third arm would be demanding in terms of operationalisation, increased sample size and statistical biases to control. The optimal strategy was deemed to be the addition of a third arm, arriving retrospectively at a simplified multi-arm multi-stage clinical trial design to achieve statistical validity. The D2EFT study maintains additional value in a quickly evolving second-line ART strategy allowed by the progress in global access to ART. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

6. Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial

Author

Hoy, Jennifer, La Rosa, Alberto, Pujari, Sanjay, Schechter, Mauro, White, David D.W., Engen, Nicole Wyman, Ensrud, Kristine E., Aagaard, Peer P.D., Carr, Andrew, Grund, Birgit, Roediger, Mollie, Schwartz, Ann A.V., Shepherd, John, Avihingsanon, Anchalee, Badal-Faesen, Sharlaa, De Wit, Stéphane, Jacoby, Simone, Hoy, Jennifer, La Rosa, Alberto, Pujari, Sanjay, Schechter, Mauro, White, David D.W., Engen, Nicole Wyman, Ensrud, Kristine E., Aagaard, Peer P.D., Carr, Andrew, Grund, Birgit, Roediger, Mollie, Schwartz, Ann A.V., Shepherd, John, Avihingsanon, Anchalee, Badal-Faesen, Sharlaa, De Wit, Stéphane, and Jacoby, Simone

Abstract

Both HIV infection and antiretroviral therapy (ART) are associated with lower bone mineral density (BMD) and increased fracture risk. Because the relative contributions of ART and untreated HIV to BMD loss are unclear, it is important to quantify the effect of ART on bone. We compared the effect of early ART initiation (CD4 >500 cells/μL) with deferred ART on change in BMD in the START Bone Mineral Density substudy, a randomized trial evaluating the effect of immediate ART initiation versus deferring ART (to CD4 <350 cells/μL). BMD was measured annually at the lumbar spine and hip by dual-energy X-ray absorptiometry (DXA). Percent change in BMD by treatment assignment (intent-to-treat analysis) was estimated using longitudinal mixed models and linear regression. Baseline and follow-up DXA scans were available for 399 (195 immediate, 204 deferred) participants (median age 32 years, 80% non-white, 26% women, median CD4 count 642 cells/μL). ART (most commonly including tenofovir and efavirenz) was used for 95% and 18% of follow-up in the immediate and deferred ART groups, respectively. Through 2.2 years mean follow-up, immediate ART resulted in greater BMD declines than deferred ART at the hip (–2.5% versus –1.0%; difference –1.5%, 95% confidence interval [CI] –2.2 to –0.8, p < 0.001) and spine (–1.9% versus –0.4%; difference –1.6%, 95% CI –2.2 to –1.0, p < 0.001). BMD declines were greatest in the first year of ART. In the immediate ART group, spine BMD stabilized after year 1, whereas hip BMD declined progressively over 2 years. After year 1, BMD changes were similar in the immediate and deferred groups. No clinical, HIV-related, or ART characteristic predicted greater BMD loss in either group. All HIV treatment guidelines now recommend ART initiation at HIV diagnosis because of the reduced risk of serious clinical outcomes. Better understanding of the longer-term consequences of the observed reductions in BMD is needed. Clinical Trials Registration: NCT00867048. © 2, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2017

8. Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial

Author

Matthews, Gail, Jacoby, Simone, Borok, Margaret, Eriobu, Nnakelu, Kaplan, Richard, Kumarasamy, Nagalingeswaran, Bennet, Jaclyn Ann, Avihingsanon, Anchalee, Chetchotisakd, Ploenchan, Wagner Cardoso, Sandra, Azwa, Iskander, Losso, Marcelo, Brown, Dannae, Arlinda, Dona, Hutchinson, Jolie, Kelleher, Anthony, Cisse, Mohamed, Dao, Sounkalo, Polizzotto, Mark, Emery, Sean, Law, Matthew, Papot, Emmanuelle, Karyana, Muhammad, Lupo, Sergio, Solari, Ana Melisa, Grinsztejn, Beatriz, Wolff, Marcello, Andrade-Villanueva, Jaime, Mosqueda Gómez, Juan Luis, Chow, Ting Soo, Mohapi, Lerato, Yunihastuti, Evy, Hadi, Usman, Katu, Sudirman, Subronto, Yanri Wijayanti, Lane, H. Clifford, and Perelis, Leonardo

Abstract

Randomised comparative data on efficacy and safety of second-line antiretroviral therapy (ART) after failure of non-nucleoside reverse transcriptase inhibitors (NNRTIs) across diverse geographical settings are scarce. The aim of this study was to evaluate optimal second-line ART for people with HIV.

Published
2024
Full Text
View/download PDF

9. Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study

Author

Pacheco, Antonio Guilherme, Beral, Valerie, Bloch, Mark ; https://orcid.org/0000-0002-1143-5013, Carey, Cate, Carr, Andrew, Cooper, David ; https://orcid.org/0000-0002-6031-6678, Courtney-Rodgers, David, Jacoby, Simone ; https://orcid.org/0000-0001-6391-9717, Leung, Julie, Petersen, Desiree, Pett, Sarah, Murray, DD ; https://orcid.org/0000-0001-8501-8661, Suzuki, K, Law, M ; https://orcid.org/0000-0002-3540-8837, Trebicka, J, Neuhaus, J, Wentworth, D, Johnson, M, Vjecha, MJ, Kelleher, AD ; https://orcid.org/0000-0002-0009-3337, Emery, S ; https://orcid.org/0000-0001-6072-8309, Aagaard, B, Aragon, E, Arnaiz, J, Borup, L, Clotet, B, Dragsted, U, Fau, A, Gey, D, Grarup, J, Hengge, U, Herrero, P, Jansson, P, Jensen, B, Jensen, K, Juncher, H, Lopez, P, Lundgren, JD, Matthews, C, Mollerup, D, Pearson, M, Phillips, A, Reilev, S, Tillmann, K, Varea, S, Angus, B, Babiker, A, Cordwell, B, Darbyshire, J, Dodds, W, Fleck, S, Horton, J, Hudson, F, Moraes, Y, Pacciarini, F, Palfreeman, A, Paton, N, Smith, N, Van Hooff, F, Bebchuk, J, Collins, G, Denning, E, DuChene, A, Fosdick, L, Harrison, M, Herman-Lamin, K, Krum, E, Larson, G, Neaton, J, Nelson, R, Quan, K, Quan, S, Schultz, T, Thompson, G, Wyman, N, Carey, C, Chan, F, Cooper, D, Courtney-Rodgers, D, Drummond, F, Harrod, M, Jacoby, S ; https://orcid.org/0000-0001-6391-9717, Kearney, L, Lin, E, Pett, S, Robson, R, Seneviratne, N, Stewart, M, Watts, E, Finley, E, Gordin, F, Sánchez, A, Standridge, B, Belloso, W, Davey, R, Duprez, D, Gatell, J, Hoy, J, Lifson, A, Pederson, C, Perez, G, Price, R, Prineas, R, Rhame, F, Sampson, J, Worley, J, Modlin, J, Beral, V, Chaisson, R, Fleming, T, Hill, C, Konecny, Pamela ; https://orcid.org/0000-0003-0166-2287, Medland, Nicholas ; https://orcid.org/0000-0003-0403-8930, Sullivan, John, Han, Anna, Pacheco, Antonio Guilherme, Beral, Valerie, Bloch, Mark ; https://orcid.org/0000-0002-1143-5013, Carey, Cate, Carr, Andrew, Cooper, David ; https://orcid.org/0000-0002-6031-6678, Courtney-Rodgers, David, Jacoby, Simone ; https://orcid.org/0000-0001-6391-9717, Leung, Julie, Petersen, Desiree, Pett, Sarah, Murray, DD ; https://orcid.org/0000-0001-8501-8661, Suzuki, K, Law, M ; https://orcid.org/0000-0002-3540-8837, Trebicka, J, Neuhaus, J, Wentworth, D, Johnson, M, Vjecha, MJ, Kelleher, AD ; https://orcid.org/0000-0002-0009-3337, Emery, S ; https://orcid.org/0000-0001-6072-8309, Aagaard, B, Aragon, E, Arnaiz, J, Borup, L, Clotet, B, Dragsted, U, Fau, A, Gey, D, Grarup, J, Hengge, U, Herrero, P, Jansson, P, Jensen, B, Jensen, K, Juncher, H, Lopez, P, Lundgren, JD, Matthews, C, Mollerup, D, Pearson, M, Phillips, A, Reilev, S, Tillmann, K, Varea, S, Angus, B, Babiker, A, Cordwell, B, Darbyshire, J, Dodds, W, Fleck, S, Horton, J, Hudson, F, Moraes, Y, Pacciarini, F, Palfreeman, A, Paton, N, Smith, N, Van Hooff, F, Bebchuk, J, Collins, G, Denning, E, DuChene, A, Fosdick, L, Harrison, M, Herman-Lamin, K, Krum, E, Larson, G, Neaton, J, Nelson, R, Quan, K, Quan, S, Schultz, T, Thompson, G, Wyman, N, Carey, C, Chan, F, Cooper, D, Courtney-Rodgers, D, Drummond, F, Harrod, M, Jacoby, S ; https://orcid.org/0000-0001-6391-9717, Kearney, L, Lin, E, Pett, S, Robson, R, Seneviratne, N, Stewart, M, Watts, E, Finley, E, Gordin, F, Sánchez, A, Standridge, B, Belloso, W, Davey, R, Duprez, D, Gatell, J, Hoy, J, Lifson, A, Pederson, C, Perez, G, Price, R, Prineas, R, Rhame, F, Sampson, J, Worley, J, Modlin, J, Beral, V, Chaisson, R, Fleming, T, Hill, C, Konecny, Pamela ; https://orcid.org/0000-0003-0166-2287, Medland, Nicholas ; https://orcid.org/0000-0003-0403-8930, Sullivan, John, and Han, Anna

Abstract

Introduction: The use of anti-retroviral therapy (ART) has dramatically reduced HIV-1 associated morbidity and mortality. However, HIV-1 infected individuals have increased rates of morbidity and mortality compared to the non-HIV-1 infected population and this appears to be related to end-organ diseases collectively referred to as Serious Non-AIDS Events (SNAEs). Circulating miRNAs are reported as promising biomarkers for a number of human disease conditions including those that constitute SNAEs. Our study sought to investigate the potential of selected miRNAs in predicting mortality in HIV-1 infected ART treated individuals. Materials and Methods: A set of miRNAs was chosen based on published associations with human disease conditions that constitute SNAEs. This case: control study compared 126 cases (individuals who died whilst on therapy), and 247 matched controls (individuals who remained alive). Cases and controls were ART treated participants of two pivotal HIV-1 trials. The relative abundance of each miRNA in serum was measured, by RTqPCR. Associations with mortality (all-cause, cardiovascular and malignancy) were assessed by logistic regression analysis. Correlations between miRNAs and CD4+ T cell count, hs-CRP, IL-6 and D-dimer were also assessed. Results: None of the selected miRNAs was associated with all-cause, cardiovascular or malignancy mortality. The levels of three miRNAs (miRs -21, -122 and -200a) correlated with IL-6 while miR-21 also correlated with D-dimer. Additionally, the abundance of miRs -31, -150 and -223, correlated with baseline CD4+ T cell count while the same three miRNAs plus miR- 145 correlated with nadir CD4+ T cell count. Discussion: No associations with mortality were found with any circulating miRNA studied. These results cast doubt onto the effectiveness of circulating miRNA as early predictors of mortality or the major underlying diseases that contribute to mortality in participants treated for HIV-1 infection.

Published
2015

10. Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial.

Author

Hoy, Jennifer F, Schechter, Mauro, White, David, Aagaard, Peer D, Carr, Andrew, Grund, Birgit, Roediger, Mollie, Engen, Nicole Wyman, Ensrud, Kristine, Schwartz, Ann V, Shepherd, John, Avihingsanon, Anchalee, Badal-Faesen, Sharlaa, de Wit, Stephane, Jacoby, Simone, La Rosa, Alberto, and Pujari, Sanjay

Abstract

ABSTRACT Both HIV infection and antiretroviral therapy (ART) are associated with lower bone mineral density (BMD) and increased fracture risk. Because the relative contributions of ART and untreated HIV to BMD loss are unclear, it is important to quantify the effect of ART on bone. We compared the effect of early ART initiation (CD4 >500 cells/μL) with deferred ART on change in BMD in the START Bone Mineral Density substudy, a randomized trial evaluating the effect of immediate ART initiation versus deferring ART (to CD4 <350 cells/μL). BMD was measured annually at the lumbar spine and hip by dual-energy X-ray absorptiometry (DXA). Percent change in BMD by treatment assignment (intent-to-treat analysis) was estimated using longitudinal mixed models and linear regression. Baseline and follow-up DXA scans were available for 399 (195 immediate, 204 deferred) participants (median age 32 years, 80% non-white, 26% women, median CD4 count 642 cells/μL). ART (most commonly including tenofovir and efavirenz) was used for 95% and 18% of follow-up in the immediate and deferred ART groups, respectively. Through 2.2 years mean follow-up, immediate ART resulted in greater BMD declines than deferred ART at the hip (-2.5% versus -1.0%; difference -1.5%, 95% confidence interval [CI] -2.2 to -0.8, p < 0.001) and spine (-1.9% versus -0.4%; difference -1.6%, 95% CI -2.2 to -1.0, p < 0.001). BMD declines were greatest in the first year of ART. In the immediate ART group, spine BMD stabilized after year 1, whereas hip BMD declined progressively over 2 years. After year 1, BMD changes were similar in the immediate and deferred groups. No clinical, HIV-related, or ART characteristic predicted greater BMD loss in either group. All HIV treatment guidelines now recommend ART initiation at HIV diagnosis because of the reduced risk of serious clinical outcomes. Better understanding of the longer-term consequences of the observed reductions in BMD is needed. Clinical Trials Registration: NCT00867048. © 2017 American Society for Bone and Mineral Research. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

11. Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count >= 300 cells/mu L who were assigned to 7.5 MIU interleukin-2

Author

Fox, Zoe, Antunes, Francisco, Davey, Rick, Gazzard, Brian, Klimas, Nancy, Labriola, Ann, Losso, Marcelo, Neaton, James D., Phillips, Andrew N., Ruxrungtham, Kiat, Staszewski, Schlomo, Weiss, Laurence, Lundgren, Jens D., Abrams, Donald I., Cooper, David A., Darbyshire, Janet H., Duncan, William R., Emery, Sean, Lane, H. Clifford, Lehrman, Sandra, Aguilar, Liliana, Betina Angel, Eleonora, Aquilia, Silvia, Belloso, Waldo, Benetucci, Jorge, Bittar, Victor, Cahn, Pedro, Casiro, Arnaldo, Contarelli, Jorge, Corral, Jorge, Daciuk, Lucia, David, Daniel, Ferrari, Ines, Fridman, Diego, Galache, Viviana, Guaragna, Graciela, Ivalo, Silvina, Laplume, Hector, Lanusse, Isabel, Lasala, Maria B., Lattes, Roberta, Lasovsky, Jaime, Lopardo, Gustavo, Lourtau, Leonardo, Lupo, Sergio, Maranzana, Aldo, Marson, Cristina, Massera, Lucila, Del Lujan Sanchez, Marisa, Somenzini, Carla, Tocci, Mariel, Algar, Sally, Anderson, Jonathan, Baker, David, Blavius, Kathy, Bloch, Mark, Boyle, Michael, Bradford, David, Britton, Phillip, Carrall, Leah, Carr, Andrew, Chuah, John, Curry, Michael, D Arcy-Evans, Clive, Dobson, Pauline, Doong, Nicholas, Egan, Cari, Ferguson, Wendy, Finlayson, Robert, French, Martyn, Frater, Anthony, Gold, Julian, Habel, Philip, Haig, Kay, Holland, Rohan, Hyland, Natalie, Hoy, Jennifer, Hudson, Jeff, James, Robyn, Leung, Jenny, Lowe, Kaye, Macrae, Karen, Mcmurchie, Marilyn, Medland, Nicholas, Miller, Samantha, Murray, Jo, Newman, Rosie, Orth, David, Patching, Julie, Primrose, Ruth, Ree, Hugo, Richardson, Robyn, Rogers, Gary, Roney, Janine, Roth, Norman, Sarangapany, Jeganathan, Shaw, David, Silberberg, Carol, Skett, Jenny, Williams, Leah, Soo, Tuck Meng, Sowden, David, Street, Alan, Vale, Robyn, Villella, Claudio, Walker, Alan, Watson, Ashley, Wendt, Ngaire, Wood, Helen, Youds, David, Aichelburg, Alexander, Rieger, Armin, Vetter, Norbert, Clumeck, Nathan, Wit, Stephane, Kabeya, Kabamba, O Doherty, Elizabeth, Amorim, Cristiane Sales, Basso, Caritas Relva, Lewi, David Salamao, Pereira, Luiz Carlos, Da Silva, Mariliza, Lobato Souza, Tamara Newman, Angel, Jonathan, Bouchard, Pierrette-Rolande, Clark, Fran, Cohen, Jeff, Dambreville, Mimose, Ellis, Michele, Fiset, Stephan, Foster, Andrea, Fraser, Christopher, Gagnon, Susan, Gilmour, Janet, Guenette, Richard, Haldane, Heather, Hawley-Foss, Nanci, Hyndman, Susan, Johnston, Lynn, Jubinville, Nathalie, Juneau, Francoise, Kelleher, Lynn, Lapointe, Lyne, Latendre-Paquette, Judy, Lindemulder, Adeline, Mashinter, Laura, Lefebvre, Eric, Mcfarland, Nancy, Morisseau, Chantal, O Neill, Robert, Piche, Alain, Ralph, Edward, Rouleau, Danielle, Routy, Jean-Pierre, Sandre, Roger, Schmidt, Shelley, Shafran, Stephen, Smaill, Fiona, Stromberg, Dale, Trepanier, Jean-Marc, Trottier, Sylvie, Veal, Susanne, Walmsley, Sharon, Weiss, Karl, Williams, Kurt, Young, Mavis, Zaleschuk, Barbara, Zarowny, Don, Baadegaard, Bente, Black, Finn, Boedker, Kirsten, Gerstoft, Jan, Jensen, Lene, Mathiesen, Lars, Nielsen, Henrik, Pedersen, Court, Petersen, Dorthe, Aboulker, Jean-Pierre, Baakili, Adyb, Bengrait, Nafissa, Bensalem, Maryse, Berthe, Huguette, Bloche, Martin, Bazin, Claude, Boue, Francois, Bouvet, Elisabeth, Brancon, Christiane, Capitant, Catherine, Ceppi, Carole, Cheneau, Christine, Coutellier, Anne, Chennebault, Jean Marie, Coquet, Fabienne, Truchis, Pierre, Delavalle, Anne-Marie, Frixon-Marin, Veronique, Gastaut, Jean-Albert, Delfraissy, Francois, Eliaszeicz, Muriel, Gallais, Herve, Gataut, Jean-Albert, Gilquin, Jacques, Gonzalez-Canali, Gustavo, Gaudebout, Chrisiane, Goujard, Cecile, Hoen, Bruno, Honore, Patricia, Jarousse, Bernard, Lang, Jean-Marie, Lefebvre, Benedict, Levy, Yves, Loison, Jocelyne, Maignan, Aline, Meynard, Jean-Luc, Michon, Christophe, Mole, Martin, Marsal, Laurence, Matheron, Sophie, Mortier, Emmanuel, Oksenhendler, Eric, Poirier, Sandrine, Picard-Dahan, Catherine, Ravaux, Isabelle, Raffi, Francois, Raguin, Gilles, Reynes, Jacque, Rozenbaum, Willy, Salmon, Dominique, Simon, Anne, Spiridon, Gabriella, Viard, Jean-Paul, Vidal, Michele, Zucman, David, Bergmann, Frank, Brockmeyer, Norbert, Faetkenheuer, Gerd, Fenske, Stefan, Gey, Daniela, Goebel, Frank-Detlef, Goetsch, Martina, Hartmann, Martin, Klinker, Hartwig, Kremer, Gisela, Mantzsch, Kathleen, Mauss, Stefan, Rockstroh, Juergen, Rotty, Jessica, Rund, Ellen, Schneider, Katrin, Schuermann, Dirk, Staszweski, Schlomo, Tilmann, Klaus, Vogel, Martin, Bentwich, Zvi, Drora, Goldstain, Kedem, Eynat, Lang, Ruth, Levi, Itzic, Maayan, Shlomo, Magen, Eli, Mamorsky, Merav, Pilpul, Anat, Pollack, Shimon, Sthoeger, Zev, Vered, Hadas, Yust, Israel, Lyons, Fiona, Mulcahy, Fiona, Rochford, Annette, Auiti, Fernando, Angarano, Gioacchino, Bertelli, Davide, Bini, Teresa, Bruno, Raffaele, Cadeo, Gian Pietro, Carosi, Giampietro, D Arminio Monforte, Antonella, Del Giacco, Sergio, Di Pietro, Massimo, Esposito, Roberto, Filice, Gaetano, Gavazzeni, Gabriella, Guaraldi, Giovanni, Indiveri, Francesco, Lazzarin, Adriano, Mazzotta, Francesco, Minolli, Lorenzo, Montroni, Maria, Moroni, Mauro, Nozza, Silvia, Pastor, Guiseppe, Poli, Guido, Raise, Enzo, Romagnani, Sergio, Rusconi, Vega, Sacchi, Paolo, Suter, Fredy, Tambussi, Giuseppe, Tirelli, Umberto, Fraser, Helen, Iwamoto, Aikichi, Kikuchi, Yoshida, Mori, Masahiko, Nakamura, Tetsuya, Odawara, Takashi, Oka, Shinichi, Shirasaka, Takuma, Takano, Misao, To, Junichiro, Ueta, Chisato, El Filali, Kamal, Erradey, Ikbale, Himmich, Hakima, Blok, W., Borleffs, J., Bravenboer, B., Bronveld, W., Claessen, F., Duurvoort, Maurice, Ferwerda, J., Frissen, P., Hulshoff, Nicolette, Juttman, Job, Kauffmann, R., Koopmans, P., Kroon, F., Lowe, Selwyn, Leemhuis, M., Meenhorst, P., Boer, Lieselotte Posthuma, Reiss, Peter, Reinders-Folmer, S., Richter, C., Santegoets, Rick, Schoemaker, Marijke, Schrey, G., Sprenger, Herman, Ten Veen, Jacob, Tessalaar, Judith, Ende, M., Vall, H., Eeden, Arne, Leeuwen, Remko, Vermeulen, Joost, Ten Kate, Reinier W., Boxtel, Renee, Eden, Arne, Ven, Bernadette, Meulen, Piet, Ten Napei, C., Vriesendrop, R., Bruun, Johann, Bakowska, Elzbieta, Beniowski, Marek, Boron-Kaczmarska, Anna, Gasiorowski, Jacek, Gxadysz, Andrzej, Horban, Andrzej, Knysz, Brygida, Mularska, Elzbieta, Pynka, Magdelena, Szymczak, Aleksandra, Aldir, Isabel, Doroana, Manuela, Duque, Luis, Mansinho, Kamal, Pinto, Inez, Valadas, Emilia, Vera, Jose, Foo, Estelle, Panchalingham, Anushia, Lim, Poh Lian, Paton, Nick, Peperstraete, Bernard, Quek, Angela, Alcazar-Caballero, Rosario, Arrizabalaga, Julio, Bouza, Emilio, Cepeda, Concepcion, Barron, Xabier, Cervero Jimenez, Miguel, Clotet, Bonaventura, Cortes, Luis, Domingo, Pere, Fernandez, Pompeyo, Fernandez-Cruz, Eduardo, Fuster, Montserrat, Gatell, Jose, Gijon, Paloma, Gil, Ignacio, Gonzales-Lahoz, Juan, Gonzalez, Alicia, Hernandez, Manuel, Iribarren, Jose, Jimenez, Miguel, Knobel, Hernando, Leon, Agathe, Carlos Lopez, Juan, Lozano, Angeles, Lopez, Paco, Moreno, Jose, Munoz, Rosa, Padilla, Belen, Parras, Angeles, Pastor, Antoni, Pedreira, Jose, Pristo, Julio, Pena, Jose, Roca, Victor, Rubio, Rafael, Sanchez Rivera, Jose, Sanz, Jesus, Tamargo, Lara, Torres, Rafael, Pehrson, Pehr O., Sandstrom, Eric, Bernasconi, Enos, Gurtner, Vanina, Magenta, Lorenzo, Ampunpong, Uangarun, Bowonwatnuwong, Chureeratana, Chanchai, Patimoaporn, Chetchotisakd, Ploenchan, Chuenyam, Thesinee, Duncombe, Chris, Horsakulthai, Mannassinee, Kantipong, Pacharee, Liddy, John, Phanuphak, Praphan, Pongsurachet, Vithaya, Seekaew, Samroeng, Sonjai, Areerat, Subsri, Nuramon, Suwanagool, Surapol, Techasathit, Wichai, Wankoon, Jaturaporn, Adebiyi, Aderonke, Aldam, Diana, Alexander, Ian, Angus, Brian, Barber, Tristan, Bonnington, Sue, Care, Chris, Carroll, Anne, Cornforth, David, Donaldson, Oscar, Druiff, Laurance, Easterbrook, Philippa, Edwards, Beverley, Ellis, Chris, Fisher, Martin, Fox, Ray, Harrison, Allan, Herman, Sandra, Heald, Lisa, Higgs, Christopher, Jendrulek, Isabelle, Johnson, Margaret, Judges, Lucy, Karim, Fatimah, Kinghorn, George, Laurenti, Julie, Lee, Christine, Leen, Clifford, Legg, Ken, Maw, Raymond, Macconachie, Alisdair, Mckernan, Sinead, Mclean, Lorna, Mcmillan, Andrew, Mguni, Sifiso, Morris, Sheila, Mulchay, Fiona, Mullan, Dee, Mullaney, Scott, Murphy, Maurice, Nunn, Andrew, Ong, Edmund, Owen, Maxine, Palfreeman, Adrian, Perry, Nicky, Peters, Barry, Pozniak, Anton, Ronan, Agnes, Skinner, Cecilia, Stroud, Carol, Takawira, Martin, Tamm, Norbert, Thomas, Rachel, Yee, Thynn Thynn, Vanthuyne, An, Wansborough-Jones, Mark, Weber, Jonathan, White, David, Wilkins, Ed, Wiselka, Martin, Williams, Ian, Waugh, Mike, Wotherspoon, Joyce, Youle, Mike, Doyle, Margaret, Goodwin, Edward, Luskin-Hawk, Roberta, Sullivan, James, Verheggen, Rita, Abrams, Donald, Baxter, John, Besch, C. Lynn, Child, Carroll, Cohn, David, Cooper, Pam, El-Sadr, Wafaa, Farrough, Martha, Fisher, Evelyn, Fuentes, Luis, Gordin, Fred, Graeber, Carol, Kelly, Mary Ellen, Kostman, Jay, Lattanzi, Kelly, Macarthur, Rodger, Makohon, Linda, Markowitz, Norman P., Martinez, Norma, Mastro-Polak, Diane, Mitchell, Vinnie, Mushatt, David, Patterson, Kathryn, Perez, George, Rosmarin, Corey, Rouff, Jack R., Saldanha, Jennifer, Sampson, James, Sawyer, Robert, Standridge, Barbara, Sweeton, Bentley, Tedaldi, Ellen, Thompson, Melanie, Valencia, Patricia, Verlinghieri, Gwen, Walker, Janice, Watson, Vicky, Williams, Bruce, Armstrong, Adam, Banks, Susan, Blazes, David, Barile, Anthony, Coelho, Linda, Dennis, Marilyn, Flaks, Hannah, Gilcrest, Joyce, Gittens, Kathleen, Hopper, Shelia, Humphries, M. J., Spooner, Katherine, Tamminga, Cindy L., Vita, Jean, Wegner, Scott A., Wortmann, Glenn, Bisby, Nicole, Blake, William, Brown, Sheldon, Chilliade, Phillippe, Cole, Teresa, Elliot, Katherine, Geisler, Christiane, Goetz, Matthew, Gomez-Perez, Elizabeth, Helman, Jami, Nahass, Ronald, Leflore, Dirk, Marston, Barbara, Obregon, Maria, Petrolati, Jennifer, Pitrak, David L., Roland, Robert, Rosa, Carol, Rossman, Barbara, Schlueter Wirtz, Susan, Schuck, Suzanne, Scretchings, Tiffany, Simon, Gary, Smith, Mack, Summers, Kimberley, Werhane, Mary Jo, Arduino, Roberto, Bell, Brian, Breaux, Katherine, Cuervo, Hilda, Hale, Carl, Lewis, Stanley, Mall, Mark, Mora, Fransisco, Diez, Martine M., Okhuysen, Pablo, Rodriguez-Barradas, Maria, Schrader, Shannon R., Healy, Lynn, Kaszubski, Chris, Kolber, Michael, Tanner, Tom, Armstrong, Joann, Dahlke, Jennifer, Johnson, Leonard, Kaminski, Patricia, Rhame, Frank, Shoden, Cheryl, Temesgen, Zelalem, Urbanich, Marcy, Valenti, Sharon, Zervos, Marcus, Barrick, Bill, Chaitt, Doreen, Hahn, Barbara, Lane, Cliff, Martell, Dennis, Mcnay, Laura, Metcalf, Julia, Powers, April, Tavel, Jorge A., Loveless, Karen, Peterson, Sue, Sweek, Suzanne, Albrecht, Helmut, Antoine, Nicole, Pell, Paula, Gatell, Jose Maria, Hoy, Jenny, Lifson, Alan, Pederson, Court, Borup, Liselotte, Dragsted, Ulrik Bak, Greve, Anne Fau, Jensen, Karoline, Jens Lundgren, Mollerup, David, Pearson, Mary, Phillips, Andrew, Aboulhab, Jamila, Babiker, Abdel, Cordwell, Brooke, Darbyshire, Janet, Hack, Lisa, Hooker, Malcolm, Moraes, Yolanda, Newberry, Douglas, Nuwagaba-Biribonwoha, Harriet, Hooff, Fionna, Denning, Eileen, Holland Klemme, Leslie, Carey, Cate, Chan, Fonnie, Cooper, David, Courtney-Rodgers, David, Drummond, Fraser, Jacoby, Simone, Law, Matthew, Stewart, Morgan, Pett, Sarah, Alloo, Zarina, Bebchuk, Judy, Bollenbeck, Patty, Duchene, Alain G., Fosdick, Lisa, Harrison, Merrie, Krum, Eric, Larson, Gregg, Meger, Sue, Neaton, James, Nelson, Ray, Quan, Siu-Fun L., Schultz, Terri, Telke, Susan, Thackeray, Lisa, Thompson, Greg, Wentworth, Deborah, Wyman, Nicole, Duncan, William, Ferguson, Elaine, Fox, Lawrence, Gettinger, Nikki, Herrera, Janet, Luzar, Mary Anne, Maeshiro, Mieko, Martinez, Ana, Oseekey, Karen, Baigent, Greg, Capra, William, Duliege, Anne-Marie, Fitzgerald, Linda, Kwakkelstein, Marthin, Maral, Jean, O Hara, Mary, Sahner, David, Weber, Claire, Adam-Perchec, Christine, Barron, Nigel, Bell, Mary Louise, Dolan, Sandra, Eckstrand, Julie, Hicks, Steven, Mcauley, George, Beck, Sharon, Brown, Shawn, and Rupert, Adam

Catalog

Books, media, physical & digital resources
See catalog results